期刊文献+

HPTH(1-34)及hPTHrP(1-34)的结构与功能的关系 被引量:3

The Relationship of the Structures and Functions of hPTH(1-34) and hPTHrP(1-34)
下载PDF
导出
摘要 对各种结构研究及检测方法所得hPTH(1-34)及hPTHrP(1-34)的空间结构进行综合整理,探讨其结构与功能的关系及其应用意义。分别以N端,C端,连接区为着眼点,对hPTH(1-34)及hPTHrP(1-34)在溶液中的构象及其晶体结构进行综述,讨论了特定氨基酸对该多肽的激动剂活性以及受体结合活性的影响,并对这些影响在该多肽结构改造上的意义进行了展望 hPTH(1-34)及hPTHrP(1-34)是由负责生理活性的N端和负责受体结合的C端以及结构随环境而改变的连接区组成的。对hPTH(1-34)及hPTHrP(1-34)结构知识的深入了解必将对理论研究及临床实践产生重要意义。 To sum up and put in order the results of the spacial structures of hPTH( 1-34) and hPTHrP( 1-34) acquired from various structure researches and assays, and consult the relationship between the structures and functions and the practical significance. In light of N-termini, C-termini and the linker region, conformations in solution and crystal structures of hPTH(1-34) and hPTHrP(1-34) were reviewed according to the papers recently reported in the home and oversea journals, the effects of any definite amino acids on the agonist activity and receptor binding capacity were discussed, the significance of those effect on the peptide's structure modification was prospected. hPTH(1-34) and hPTHrP( 1-34) consist of N termini which are responsible for agonist activity, C termini which are responsible for receptor binding, and the linker regions whose conformations always change along with the environment. Great and far-reaching significance will be produced by comprehending the structure information of hPTH(1-34) and hPTHrP(1-34).
出处 《药物生物技术》 CAS CSCD 2003年第6期394-400,共7页 Pharmaceutical Biotechnology
关键词 人甲状旁腺素 人甲状旁腺素相关蛋白 空间结构 构效关系 柔性 hPTH, hPTHrP, Spacial structure, Structure-activity relationship, Flexibility
  • 相关文献

参考文献1

共引文献2

同被引文献35

  • 1胡超,董立厚,王颖,韩敏,勾忠平,郑莉.2种注射用重组人甲状旁腺素健康人体生物等效性研究[J].中国新药杂志,2020,29(3):293-298. 被引量:2
  • 2李克坚,杨化新,梁成罡,徐康森.重组人甲状旁腺激素效价测定方法的研究[J].药物生物技术,2005,12(1):43-45. 被引量:4
  • 3ROSEN C J. What's new with PTH in osteoporosis where are we and where are we headed? [J]. Trends Endocrinol Metab, 2004,15(5):229-233.
  • 4ROSEN C J, BILEZIKIAN J P. Anabolic therapy for osteoporosis [J]. J Clin Endocrinology Metab, 2001,86(3): 957-964.
  • 5COSMAN F, NIEVES J, WOELFERT L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal[J]. J Bone Miner Res, 2001,16(5):925-931.
  • 6NEER R M, ARNAUD C D, ARNAUD, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J]. N Engl J Med, 2001,344(19):1434-1441.
  • 7GOLTZMAN D, Interactions of PTH and PTHrp with the PTH/PTHrp receptor and downstream signaling pathways: exceptions that provide the rules[J]. JBone Miner Res, 1999, 14(2): 173-177.
  • 8HOCK J M, GERAL I, FONESCA J, et al. Human parathyroid hormone(l-34). Increases bone mass in ovariectomized and orehidectomized rats[J]. Endocrinol, 1998, 122(6):2899-2904.
  • 9DEMPSTER D W,COSMAN F,KURLAND E S, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:a paired biopsy study[J]. J Bone Miner Res,2001,16(10):1846-1853.
  • 10WRENGER S, KAHNE T, BOHUON C, et al. Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DPIV) [J]. FEBS Lett, 2000, 466 (1): 155-159.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部